194 related articles for article (PubMed ID: 24791013)
1. Multiple Functional Motifs Are Required for the Tumor Suppressor Activity of a Constitutively-Active ErbB4 Mutant.
Gallo RM; Bryant IN; Mill CP; Kaverman S; Riese DJ
J Cancer Res Ther Oncol; 2013 Aug; 1(1):10. PubMed ID: 24791013
[TBL] [Abstract][Full Text] [Related]
2. Ligand stimulation of ErbB4 and a constitutively-active ErbB4 mutant result in different biological responses in human pancreatic tumor cell lines.
Mill CP; Gettinger KL; Riese DJ
Exp Cell Res; 2011 Feb; 317(4):392-404. PubMed ID: 21110957
[TBL] [Abstract][Full Text] [Related]
3. Phosphorylation of ErbB4 on Tyr1056 is critical for inhibition of colony formation by prostate tumor cell lines.
Gallo RM; Bryant I; Fry R; Williams EE; Riese DJ
Biochem Biophys Res Commun; 2006 Oct; 349(1):372-82. PubMed ID: 16934755
[TBL] [Abstract][Full Text] [Related]
4. Constitutively active ErbB4 and ErbB2 mutants exhibit distinct biological activities.
Penington DJ; Bryant I; Riese DJ
Cell Growth Differ; 2002 Jun; 13(6):247-56. PubMed ID: 12114214
[TBL] [Abstract][Full Text] [Related]
5. A constitutively active ErbB4 mutant inhibits drug-resistant colony formation by the DU-145 and PC-3 human prostate tumor cell lines.
Williams EE; Trout LJ; Gallo RM; Pitfield SE; Bryant I; Penington DJ; Riese DJ
Cancer Lett; 2003 Mar; 192(1):67-74. PubMed ID: 12637154
[TBL] [Abstract][Full Text] [Related]
6. The Yin and Yang of ERBB4: Tumor Suppressor and Oncoprotein.
Lucas LM; Dwivedi V; Senfeld JI; Cullum RL; Mill CP; Piazza JT; Bryant IN; Cook LJ; Miller ST; Lott JH; Kelley CM; Knerr EL; Markham JA; Kaufmann DP; Jacobi MA; Shen J; Riese DJ
Pharmacol Rev; 2022 Jan; 74(1):18-47. PubMed ID: 34987087
[TBL] [Abstract][Full Text] [Related]
7. ErbB2 and ErbB3 do not quantitatively modulate ligand-induced ErbB4 tyrosine phosphorylation.
Feroz K; Williams E; Riese DJ
Cell Signal; 2002 Sep; 14(9):793-8. PubMed ID: 12034361
[TBL] [Abstract][Full Text] [Related]
8. Phosphorylation of ErbB4 on tyrosine 1056 is critical for ErbB4 coupling to inhibition of colony formation by human mammary cell lines.
Pitfield SE; Bryant I; Penington DJ; Park G; Riese DJ
Oncol Res; 2006; 16(4):179-93. PubMed ID: 17120616
[TBL] [Abstract][Full Text] [Related]
9. The ERBB4/HER4 intracellular domain 4ICD is a BH3-only protein promoting apoptosis of breast cancer cells.
Naresh A; Long W; Vidal GA; Wimley WC; Marrero L; Sartor CI; Tovey S; Cooke TG; Bartlett JM; Jones FE
Cancer Res; 2006 Jun; 66(12):6412-20. PubMed ID: 16778220
[TBL] [Abstract][Full Text] [Related]
10. ErbB2 Is Necessary for ErbB4 Ligands to Stimulate Oncogenic Activities in Models of Human Breast Cancer.
Mill CP; Zordan MD; Rothenberg SM; Settleman J; Leary JF; Riese DJ
Genes Cancer; 2011 Aug; 2(8):792-804. PubMed ID: 22393464
[TBL] [Abstract][Full Text] [Related]
11. Receptor tyrosine kinase ERBB4 mediates acquired resistance to ERBB2 inhibitors in breast cancer cells.
Canfield K; Li J; Wilkins OM; Morrison MM; Ung M; Wells W; Williams CR; Liby KT; Vullhorst D; Buonanno A; Hu H; Schiff R; Cook RS; Kurokawa M
Cell Cycle; 2015; 14(4):648-55. PubMed ID: 25590338
[TBL] [Abstract][Full Text] [Related]
12. The Q43L mutant of neuregulin 2β is a pan-ErbB receptor antagonist.
Wilson KJ; Mill CP; Gallo RM; Cameron EM; VanBrocklin H; Settleman J; Riese DJ
Biochem J; 2012 Apr; 443(1):133-44. PubMed ID: 22216880
[TBL] [Abstract][Full Text] [Related]
13. Phe45 of NRG2beta is critical for the affinity of NRG2beta for ErbB4 and for potent stimulation of ErbB4 signaling by NRG2beta*.
Hobbs SS; Gallo RM; Riese DJ
Growth Factors; 2005 Dec; 23(4):273-83. PubMed ID: 16338790
[TBL] [Abstract][Full Text] [Related]
14. Five carboxyl-terminal residues of neuregulin2 are critical for stimulation of signaling by the ErbB4 receptor tyrosine kinase.
Hobbs SS; Cameron EM; Hammer RP; Le AT; Gallo RM; Blommel EN; Coffing SL; Chang H; Riese DJ
Oncogene; 2004 Jan; 23(4):883-93. PubMed ID: 14661053
[TBL] [Abstract][Full Text] [Related]
15. Neuregulin-1 only induces trans-phosphorylation between ErbB receptor heterodimer partners.
Li Z; Mei Y; Liu X; Zhou M
Cell Signal; 2007 Mar; 19(3):466-71. PubMed ID: 16978839
[TBL] [Abstract][Full Text] [Related]
16. ErbB Receptors and Cancer.
Wang Z
Methods Mol Biol; 2017; 1652():3-35. PubMed ID: 28791631
[TBL] [Abstract][Full Text] [Related]
17. The extracellular region of ErbB4 adopts a tethered conformation in the absence of ligand.
Bouyain S; Longo PA; Li S; Ferguson KM; Leahy DJ
Proc Natl Acad Sci U S A; 2005 Oct; 102(42):15024-9. PubMed ID: 16203964
[TBL] [Abstract][Full Text] [Related]
18. Presenilin-dependent gamma-secretase processing regulates multiple ERBB4/HER4 activities.
Vidal GA; Naresh A; Marrero L; Jones FE
J Biol Chem; 2005 May; 280(20):19777-83. PubMed ID: 15746097
[TBL] [Abstract][Full Text] [Related]
19. Nuclear ErbB4 signaling through H3K9me3 is antagonized by EGFR-activated c-Src.
Ishibashi K; Fukumoto Y; Hasegawa H; Abe K; Kubota S; Aoyama K; Kubota S; Nakayama Y; Yamaguchi N
J Cell Sci; 2013 Jan; 126(Pt 2):625-37. PubMed ID: 23230144
[TBL] [Abstract][Full Text] [Related]
20. Desensitization by different strategies of epidermal growth factor receptor and ErbB4.
Yamamoto H; Higa-Nakamine S; Noguchi N; Maeda N; Kondo Y; Toku S; Kukita I; Sugahara K
J Pharmacol Sci; 2014; 124(3):287-93. PubMed ID: 24553453
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
